Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase 2

Gynecologic Oncology

Volumn 62, Issue 1, 1996, Pages 89-99

  Young, Timothy N ^a   Rodriguez, Gustavo C ^a   Rinehart, Alex R ^a   Robert C Jr , Bast ^b   Pizzo, Salvatore V ^a   Stack, M Sharon ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE;

ADENOCARCINOMA; ARTICLE; CANCER INVASION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LOCALIZATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MEMBRANE DAMAGE; METASTASIS POTENTIAL; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0042588489     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0195     Document Type: Article

References (70)

1. 1. Liotta, L. A., Rao, C. N., and Wewer, U. M. Biochemical interactions of tumor cells with the basement membrane, Annu. Rev. Biochem. 55, 1037-1057 (1986).
2. 2. Yurchenco, P. D., and Schittny, J. C. Molecular architecture of basement membranes, FASEB J. 4, 1577-1590 (1990).
3. 3. Mignatti, P., and Rifkin, D. B. Biology and biochemistry of proteinases in tumor invasion, Physiol. Rev. 73, 161-195 (1993).
4. 4. Moore, D. H. Primary surgical management of early epithelial ovarian carcinoma, In Ovarian Cancer (S. C. Rubin and G. P. Sutton, Eds.), McGraw-Hill, New York (1993).
5. 5. Folkman, J. Tumor angiogenesis, Adv. Cancer Res. 19, 331-358 (1974).
6. 6. Docherty, A. J. P., and Murphy, G. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins, Ann. Rheum. Dis. 49, 469-479 (1990).
7. 7. Liotta, L. A., and Stetler-Stevenson, W. G. Metalloproteinases and cancer invasion, Semin. Cancer Biol. 1, 99-106 (1990).
8. 8. Tryggvason, K., Hoyhtya, M., and Pyke, C. Type IV collagenases in invasive tumors, Breast Cancer Res. Treat. 24, 209-218 (1993).
9. 9. Liotta, L. A., Abe, S., Robey, P. G., and Martin, G. R. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor, Proc. Natl. Acad. Sci. USA 76, 2268-2272 (1979).
10. 10. Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, L., Foltz, C. M., and Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen, Nature 284, 67-68 (1980).
11. 11. Turpeenniemi-Hujanen, T., Thorgeirsson, U. P., Hart, I. R., Grant, S., and Liotta, L. A. Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential, J. Natl. Cancer Inst. 75, 99-108 (1985).
12. 12. Garbisa, S., Pozzati, R., Muschel, R. J., Saffiotti, U., Ballin, M., Goldfarb, R. H., Koury, G., and Liotta, L. Secretion of type IV collagenolytic protease and metastatic phenotype: Induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-Ela., Cancer Res. 47, 1523-1528 (1987).
13. 13. Nakajima, M., Welch, D., Belloni, P. N., and Nicolson, G. L. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials, Cancer Res. 47, 4869-4876 (1987).
14. 14. Nakajima, M., Lotan, D., Baig, M. M., Carralero, R. M., Wood, W. R., Hendrix, M. J. C., and Lotan, R. Inhibition by retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells, Cancer Res. 49, 1698-1706 (1989).
15. 15. Ura, H., Bonfil, R. D., Reich, R., Reddel, R., Pfeifer, A., Harris, C. C., and Klein-Szanto, A. J. P. Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human broncial epithelial cells, Cancer Res. 49, 4615-4621 (1989).
16. 16. Frisch, S. M., Reich, R., Collier, I. E., Genrich, L. T., Martin, G., and Goldberg, G. I. Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells, Oncogene 5, 75-83 (1990).
17. 17. Bernhard, E. J., Gruber, S. B., and Muschel, R. J. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/ collagenase) to the metastatic phenotype in transformed rat embryo cells, Proc. Natl. Acad. Sci. USA 91, 4293-4297 (1994).
18. 18. Monteagudo, R., Merino, M., San-Juan, J., Liotta, L. A., and Stetler-Stevenson, W. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue, Am. J. Pathol. 136, 585-592 (1990).
19. r 72,000 type IV collagenase in human colonic adenocarcinoma, Cancer Res. 51, 439-444 (1991).
20. 20. Campo, E., Merino, M. J., Liotta, L., Neumann, R., and Stetler-Stevenson, W. Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue, Hum. Pathol. 23, 1395-1401 (1992).
21. 21. Brown, P. D., Bloxidge, R. E., Stuart, N. S. A., Gatter, K. C., and Carmichael, J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma, J. Natl. Cancer Inst. 85, 574-578 (1993).
22. r 72,000) expression in human prostate: benign and malignant tissue, Cancer Res. 53, 878-883 (1993).
23. 23. Davies, B., Miles, D. W., Happerfield, L. C., Naylor, M. S., Bobrow, L. G., Rubens, R. D., and Balkwill, F. R. Activity of type IV collagenases in benign and malignant breast disease, Br. J. Cancer 67, 1126-1131 (1993).
24. r 92,000 type IV collagenase in human brain tumors, Cancer Res. 53, 2208-2211 (1993).
25. 25. Schultz, R. M., Silberman, S., Persky, B., Bajowski, A. S., and Carmichael, D. F. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells, Cancer Res. 48, 5539-5545 (1988).
26. 26. Khokha, R., Waterhouse, P., Yagel, S., Lala, P. K., Overall, C. M., Norton, G., and Denhardt, D. T. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells, Science 243, 947-950 (1989).
27. 27. Alvarez, O. A., Carmichael, D. F., and DeClerck, Y. A. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases, J. Natl. Cancer Inst. 82, 589-595 (1990).
28. 28. Albini, A., Melchiori, A., Santi, L., Liotta, L. A., Brown, P. D., and Stetler-Stevenson, W. G. Tumor cell invasion inhibited by TIMP-2, J. Natl. Cancer Inst. 83, 775-779 (1991).
29. 29. Alexander, C. M., and Werb, Z. Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro, J. Cell Biol. 118, 727-739 (1992).
30. 30. Testa, J. Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, HEp-3, is accompanied by increased expression of tissue inhibitor of metalloproteinases-2, Cancer Res. 52, 5597-5603 (1992).
31. 31. Niedbala, M. J., Crickard, K., and Bernacki, R. J. In vitro degradation of extracellular matrix by human ovarian carcinoma cells, Clin. Exp. Metastasis 5, 181-197 (1987).
32. 32. Kanemoto, T., Martin, G. R., Hamilton, T. C., and Fridman, R. Effects of synthetic peptides and protease inhibitors on the interaction of a human ovarian cancer cell line (NIH:OVCAR-3) with a reconstituted basement membrane (Matrigel), Invasion Metastasis 11, 84-92 (1991).
33. 33. Kobayashi, H., Ohi, H., Sugimura, M., Shinohara, H., Fujii, T., and Terao, T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B, Cancer Res. 52, 3610-3614 (1992).
34. 34. Davies, B., Brown, P. D., East, N., Crimmin, M. J., and Balkwill, F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts, Cancer Res. 53, 2087-2091 (1993).
35. 35. Young, T. N., Rodriguez, G. C., Moser, T. L., Bast, R. C., Jr., Pizzo, S. V., and Stack, M. S. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium, Am. J. Obstet. Gynecol. 170, 1285-1296 (1994).
36. 36. Moser, T. L., Young, T. N., Rodriguez, G. C., Pizzo, S. V., Bast, R. C., Jr., and Stack, M. S. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int. J. Cancer 56, 552-559 (1994).
37. 37. Karlan, B. Y., Amin, W., Band, V., Zurawski, V. R., Jr., and Littlefield, B. A. Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro, Gynecol. Oncol. 31, 103-112 (1988).
38. 38. Autio-Harmainen, H., Karttunen, T., Hurskainen, T., Hoyhtya, M., Kauppila, A., and Tryggvason, K. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors, Lab. Invest. 69, 312-321 (1993).
39. 39. Miyagi, E., Yasumitsu, H., Hirahara, F., Minaguchi, H., Koshikawa, N., Miyazaki, K., and Umeda, M. Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells, Jpn. J. Cancer Res. 86, 568-576 (1995).
40. 40. Okada, Y., Morodomi, T., Enghild, J. J., Suzuki, K., Yasui, A., Nakanishi, I., Salvesen, G., and Nagase, H. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts: Purification and activation of the precursor and enzymic properties, Eur. J. Biochem. 194, 721-730 (1990).
41. 41. Rodriguez, G. C., Berchuck, A., Whitaker, R. S., Schlossman, D., Clarke-Pearson, D., and Bast, R. C., Jr. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer: Relationship between receptor expression and response to epidermal growth factor, Am. J. Obstet. Gynecol. 164, 745-750 (1991).
42. 42. Stack, M. S., Rinehart, A. R., and Pizzo, S. V. Comparison of plasminogen binding and activation on extracellular matrices produced by vascular smooth muscle and endothelial cells, Eur. J. Biochem. 226, 937-943 (1994).
43. 1-proteinase inhibitor binds to extracellular matrix in vitro, Am. J. Respir. Cell Mol. Biol. 9, 666-679 (1993).
44. 44. Golub, L. M., Ramamurthy, N. S., McNamara, T. F., Greenwald, R. A., and Rifkin, B. R. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs, Crit. Rev. Oral Biol. Med. 2, 297-322 (1991).
45. 45. Heussen, C., and Dowdle, E. B. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymenzed substrates, Anal. Biochem. 102, 196-202 (1980).
46. 46. Laemmli, UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature 227, 680-685 (1970).
47. 47. Leco, K. J., Khokha, R., Pavloff, N., Hawkes, S. P., and Edwards, D. R. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues, J. Biol. Chem. 269, 9352-9360 (1994).
48. 48. Stetler-Stevenson, W. G., Krutzsch, H. C., Wacher, M. P., Margulies, I. M. K., and Liotta, L. A. The activation of human type IV collagenase proenzyme: Sequence identification of the major conversion product following organomercurial activation, J. Biol. Chem. 264, 1353-1356 (1989).
49. 49. Stack, M. S., Emberts, C., and Gray, R. D. Application of N-carboxyalkyl peptides to the inhibition and affinity purification of the porcine matrix metalloproteinases collagenase, gelatinase, and stromelysin, Arch. Biochem. Biophys. 287, 240-249 (1991).
50. 50. Stack, M. S., and Gray, R. D. Comparison of vertebrate collagenase and gelatinase using a new fluorogenic substrate peptide, J. Biol. Chem. 264, 4277 (1989).
51. 51. Matsudaira, P. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes, J. Biol. Chem. 262, 10035 (1987).
52. 52. Mignatti, P., Robbins, E., and Rifkin, D. B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade, Cell 47, 487-498 (1986).
53. 53. Ossowski, L. Invasion of connective tissue by human carcinoma cell lines: Requirement for urokinase, urokinase receptor, and interstitial collagenase, Cancer Res. 52, 6754-6760 (1992).
54. 54. Kleinman, H. K., McGarvey, M. L., Kassel, J. R., Star, V. L., Cannon, F. B., Laurie, G. W., and Martin, G. R. Basement membrane complexes with biological activity, Biochemistry 25, 312-318 (1986).
55. 55. Albini, A., Iwamoto, Y., Kleinman, H. K., Martin, G. R., Aaronson, S. A., Kozlowski, J. M., and McEwan, R. N. A rapid in vitro assay for quantitating the invasive potential of tumor cells, Cancer Res. 47, 3239-3245 (1987).
56. 56. Stetler-Stevenson, W. G., Krutzsch, H. C., and Liotta, L. A. Tissue inhibitor of metalloproteinase (TIMP-2): A new member of the metalloproteinase inhibitor family, J. Biol. Chem. 264, 17374-17378 (1989).
57. 57. Goldberg, G. I., Manner, B. L., Grant, G. A., Eisen, A. Z., Wilhelm, S., and He, C. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteinase designated TIMP-2, Proc. Natl. Acad. Sci. USA 86, 8207-8211 (1989).
58. 58. Collier, I. E., Wilhelm, S. M., Eisen, A. Z., Marmer, B. L., Grant, G. A., Seltzer, J. L., Kronberger, A., He, C., Bauer, E. A., and Goldberg, G. I. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen, J. Biol. Chem. 263, 6579-6587 (1988).
59. 59. Aimes, R. T., and Quigley, J. P. Matrix metalloproteinase-2 is an interstitial collagenase: Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4-and 1/4-length fragments, J. Biol. Chem. 270, 5872-5876 (1995).
60. 60. Silverberg, E., Boring, C., and Squires, T. Cancer statistics, CA 40, 9 (1990).
61. 61. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. A matrix metalloproteinase expressed on the surface of invasive tumor cells, Nature 370, 61-65 (1994).
62. 62. Takino, T., Sato, H., Shinagawa, A., and Seiki, M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) from a human placental cDNA library: MT-MMP's form a unique membrane-type subclass in the MMP family, J. Biol. Chem. 270, 23013-23020 (1995).
63. 63. Crabbe, T., Smith, B., O'Connell, J. P., and Docherty, A. J. P. Human progelatinase A can be activated by matrilysin, FEBS Lett. 345, 14-16 (1994).
64. 64. Okada, Y., Gonoji, Y., Naka, K., Tomita, K., Nakanishi, I., Iwata, K., Yamashita, K., and Hayakawa, T. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells: Purification and activation of the precursor and enzymic properties, J. Biol. Chem. 267, 21712-21719 (1992).
65. 65. Ogata, Y., Enghild, J. J., and Nagase, H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9, J. Biol. Chem. 267, 3581-3584 (1992).
66. 66. Okada, Y., Harris, E. D., Jr., and Nagase, H. The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts: Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate, Biochem. J. 254, 731-741 (1988).
67. 67. Nagase, H., Suzuki, K., Morodomi, T., Enghild, J. J., and Salvesen, G. Activation mechanisms of the precursors of matrix metalloproteinases 1, 2, and 3, Matrix (Suppl. 1), 237-244 (1992).
68. 68. Murphy, G., Nguyen, Q., Cockett, M. I., Atkinson, S. J., Allan, J. A., Knight, C. G., Willenbrock, F., and Docherty, A. J. P. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant, J. Biol. Chem. 269, 6632-6636 (1994).
69. 69. Strongin, A. Y., Marmer, B. L., Grant, G. A., and Goldberg, G. I. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2, J. Biol. Chem. 268, 14033-14039 (1993).
70. 70. Young, T. N., Pizzo, S. V., and Stack, M. S. A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase 2, J. Biol. Chem. 270, 999-1002 (1995).